Data / Drug companies / Eisai Inc.
Eisai Inc.: 28 products in the FDA NDC directory, labeler code 62856
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Eisai Inc. (labeler code 62856) lists 28 products in the FDA National Drug Code Directory, covering 8 finished drugs by generic name. By type: 28 prescription drugs. Its main marketing category is new drug applications (NDA). The newest product started marketing on July 13, 2026.
The request: Watch Eisai Inc. (FDA labeler code 62856): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 62856
- Products in commercial distribution
- 28
- Packages
- 41
- Finished drugs by generic name
- 8
- Prescription products
- 28
- Over the counter products
- 0
- Controlled substance products
- Schedule III 7, Schedule IV 2
- Flagged as original packager
- 20 of 20 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- November 25, 1996
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| New drug applications (NDA) | 24 | 85.7% |
| Biologics (BLA) | 4 | 14.3% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 28 | 100% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Lenvatinib | 8 | 1 |
| Perampanel | 7 | 6 |
| Rufinamide | 3 | 12 |
| Donepezil hydrochloride | 3 | 34 |
| Lecanemab | 2 | 1 |
| Lecanemab-irmb | 2 | 1 |
| Lemborexant | 2 | 1 |
| Eribulin mesylate | 1 | 17 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, film coated | 7 | 25% |
| Tablet | 6 | 21.4% |
| Capsule | 5 | 17.9% |
| Injection, solution | 4 | 14.3% |
| Kit | 3 | 10.7% |
| Suspension | 2 | 7.1% |
| Injection | 1 | 3.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
| Class | Products |
|---|---|
| Noncompetitive AMPA Glutamate Receptor Antagonist | 7 |
| Kinase Inhibitor | 5 |
| Amyloid Beta-directed Antibody | 4 |
| Cholinesterase Inhibitor | 3 |
| Orexin Receptor Antagonist | 2 |
| Microtubule Inhibitor | 1 |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Lecanemab autoinjector | 62856-222 | Injection, solution | Biologics (BLA) | July 13, 2026 |
| Lecanemab autoinjector | 62856-220 | Injection, solution | Biologics (BLA) | August 29, 2025 |
| Leqembi | 62856-215 | Injection, solution | Biologics (BLA) | January 6, 2023 |
| Leqembi | 62856-212 | Injection, solution | Biologics (BLA) | January 6, 2023 |
| Dayvigo | 62856-410 | Tablet, film coated | New drug applications (NDA) | April 7, 2020 |
| Dayvigo | 62856-405 | Tablet, film coated | New drug applications (NDA) | April 7, 2020 |
| Lenvima | 62856-712 | Capsule | New drug applications (NDA) | August 15, 2018 |
| Lenvima | 62856-704 | Capsule | New drug applications (NDA) | August 15, 2018 |
| Lenvima | 62856-718 | Kit | New drug applications (NDA) | May 13, 2016 |
| Lenvima | 62856-708 | Capsule | New drug applications (NDA) | May 13, 2016 |
| Fycompa | 62856-290 | Suspension | New drug applications (NDA) | April 30, 2016 |
| Lenvima | 62856-724 | Kit | New drug applications (NDA) | February 13, 2015 |
| Lenvima | 62856-720 | Capsule | New drug applications (NDA) | February 13, 2015 |
| Lenvima | 62856-714 | Kit | New drug applications (NDA) | February 13, 2015 |
| Lenvima | 62856-710 | Capsule | New drug applications (NDA) | February 13, 2015 |
| Fycompa | 62856-282 | Tablet | New drug applications (NDA) | October 22, 2012 |
| Fycompa | 62856-280 | Tablet | New drug applications (NDA) | October 22, 2012 |
| Fycompa | 62856-278 | Tablet | New drug applications (NDA) | October 22, 2012 |
| Fycompa | 62856-276 | Tablet | New drug applications (NDA) | October 22, 2012 |
| Fycompa | 62856-274 | Tablet | New drug applications (NDA) | October 22, 2012 |
| Fycompa | 62856-272 | Tablet | New drug applications (NDA) | October 22, 2012 |
| Banzel | 62856-584 | Suspension | New drug applications (NDA) | March 3, 2011 |
| Halaven | 62856-389 | Injection | New drug applications (NDA) | November 15, 2010 |
| Aricept | 62856-247 | Tablet, film coated | New drug applications (NDA) | July 23, 2010 |
| Banzel | 62856-583 | Tablet, film coated | New drug applications (NDA) | November 14, 2008 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.